<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972032</url>
  </required_header>
  <id_info>
    <org_study_id>E-IUS</org_study_id>
    <nct_id>NCT04972032</nct_id>
  </id_info>
  <brief_title>Efficacy of Estrogen-intrauterine Stent System After Intrauterine Adhesiolysis</brief_title>
  <official_title>Prevention of Postoperative Adhesion Recurrence by Estrogen-intrauterine Stent System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Limin Feng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, single-blinded,multi-center trial to compare the efficacy&#xD;
      of an Estrogen-intrauterine stent system with foley balloon combined with intrauterine&#xD;
      cross-linked sodium hyaluronate gel in the prevention of intrauterine adhsion recurrence&#xD;
      after hysteroscopic adhesiolysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients suspect to be suffering from IUA will be recruited following a systematic&#xD;
      pre-operative assessment process. This will include a detailed history of the menstrual&#xD;
      pattern, previous intrauterine surgery, and reproductive history, as well as 3D transvaginal&#xD;
      ultrasound. The severity and extent of intrauterine adhesions will be scored according to the&#xD;
      AFS score. All patients will receive hysteroscopic adhesiolysis with the aid of ultrasound&#xD;
      guidance as necessary. After adhesiolyis, the patients will assigned to two groups&#xD;
      randomly,namely,the E-IUS(estrogen intrauterine stent system) group and the control group.&#xD;
      Adhesion will be evaluated by hysteroscopy at second-look hysteroscopy before 60 after&#xD;
      surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative adhesion recurrence rate(%)</measure>
    <time_frame>60 days</time_frame>
    <description>The severity of adhesion will be assessed by hysteroscopy before and on d60 after surgery using the America Fertility Score (AFS) system. If the AFS score on D60 second-look hysteroscopy over 0 will be considered as adhesion recurrence. Post-operative adhesion recurrence rate(%)=(patients whose AFS score &gt;0-point after surgery/All patients after surgery)X100%. The recurrence rate (%) is range from 0(Mini) to 100(Max).The lower the recurrence means the patient has a better post-operative outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Menstrual improvement rate %(PBAC score)</measure>
    <time_frame>60 days</time_frame>
    <description>Menstrual improvement rate (evaluated by PBAC score) on 60 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate%</measure>
    <time_frame>1-2 years</time_frame>
    <description>Pregnancy rate%=Number of patients with successful Pregnancy /Number of all patients）X100%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>Intrauterine Adhesion</condition>
  <arm_group>
    <arm_group_label>Estrogen Intrauterine Stent System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An Intrauterine Stent System with estrogen will be introduced into the uterine cavity after TCRA(transcervical resection of adheison).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Foley balloon combined with self-cross-link sodium hyaluronate gel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will be given Foley balloon (manufacturer: Zhanjiang Star Enterprise Co., Ltd.) combined with self-cross-linked sodium hyaluronate gel (manufacturer: BioRegen Biomedical (Changzhou) Co., Ltd.) after TCRA surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Estrogen Intrauterine Stent System</intervention_name>
    <description>A Estrogen Intrauterine Stent System（E-IUS）will be introduced post-operatively. The E-IUS will be removed 60 days after surgery with continuous dydrogesterone administration for 5 days at 20 mg/d, and routine management.</description>
    <arm_group_label>Estrogen Intrauterine Stent System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Foley balloon combined with self-cross-link sodium hyaluronate gel</intervention_name>
    <description>Foley balloon combined with self-crosslinking sodium hyaluronate gel will be introduced post-operatively，2 cycles of estrogen-progestin sequential therapy comprised of continuous estrogen and progestin added in the second half of the cycle or continuous estradiol valerate for 60 days, followed by dydrogesterone for 10 days</description>
    <arm_group_label>Foley balloon combined with self-cross-link sodium hyaluronate gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients aged 18-40 years;&#xD;
&#xD;
               -  Meets the diagnostic criteria for moderate to severe uterine adhesions;&#xD;
&#xD;
                    -  Has the indication for TCRA surgery and is intending to undergo TCRA&#xD;
                       surgery;&#xD;
&#xD;
                         -  Female subjects are not breastfeeding at the time of the screening&#xD;
                            visit; ⑤ Voluntary acceptance of the treatment and has signed the&#xD;
                            informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergic reactions to or contraindications for silicone rubber materials,&#xD;
             estradiol and its metabolites, Foley balloon catheters and/or intrauterine&#xD;
             cross-linked sodium hyaluronate gel;&#xD;
&#xD;
               -  Presence of contraindications for TCRA surgery;&#xD;
&#xD;
                    -  Requires oral hormonal medications for a prolonged period of time;&#xD;
&#xD;
                         -  Has used high-dose estrogen medication within one month prior to&#xD;
                            surgery;&#xD;
&#xD;
                              -  Suffering from diseases such as genital tract tuberculosis, acute&#xD;
                                 genital tract inflammation, pelvic inflammatory disease, abnormal&#xD;
                                 uterine bleeding caused by systemic disease or malignant tumours&#xD;
                                 of the genital organs; ⑥ Perimenopausal and menopausal females;&#xD;
&#xD;
                                 ⑦ Comorbid with severe primary diseases of the cardiovascular,&#xD;
                                 cerebrovascular, hepatic, renal or hematopoietic system, or peptic&#xD;
                                 ulcer disease, or severe diseases affecting patient survival (such&#xD;
                                 as tumours or AIDS), or mental illness;&#xD;
&#xD;
                                 ⑧ Drug or alcohol dependence;&#xD;
&#xD;
                                 ⑨ Has enrolled in other clinical trials within the last 1 month;&#xD;
&#xD;
                                 ⑩ Patients with factors considered by the investigators to be&#xD;
                                 unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The female patients after TCRA surgery</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Limin Feng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Limin Feng</last_name>
    <phone>+86 010-59976607</phone>
    <email>lucyfeng1966@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>YiPuRun (Shanghai) Biotechnology Co.,Ltd.</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Lu</last_name>
      <phone>+8613482201715</phone>
      <email>jlu@puyibio.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Limin Feng</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <keyword>Intrauterine adhesion</keyword>
  <keyword>recurrence</keyword>
  <keyword>estrogen</keyword>
  <keyword>intrauterine stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

